Literature DB >> 10792392

Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization.

P Eggleton1, F J Ward, S Johnson, M A Khamashta, G R Hughes, V A Hajela, M Michalak, E F Corbett, N A Staines, K B Reid.   

Abstract

Extracellular calreticulin (CRT) as well as anti-CRT antibodies have been reported in patients with various autoimmune disorders and CRT has been implicated in 'epitope spreading' to other autoantigens such as the Ro/SS-A complex. In addition, antibodies against parasite forms of the endoplasmic reticulum chaperone, CRT, have been found in patients suffering from onchocerciasis and schistosomiasis. In this study, we screened sera for anti-CRT antibodies from patients with active and inactive systemic lupus ertythematosus (SLE) and primary or secondary Sjögren's syndrome. Approximately 40% of all SLE patients were positive for anti-CRT antibodies. The antigenic regions of CRT were determined using full length CRT and fragments of CRT prepared in yeast and Escherichia coli, respectively. Synthetic 15mer peptides corresponding to the major autoantigenic region of CRT (amino acids 1-289), each one overlapping by 12 amino acids, were used to map the B cell epitopes on the CRT protein recognized by autoimmune sera. Major antigenic epitopes were found to be associated with the N-terminal half of the protein in 69% of the SLE sera from active disease patients, while the C-domain was not antigenic. Major epitopes were found to be reactive with antibodies in sera from SLE patients with both active and inactive disease, spanning different regions of the N and P-domains. Sera from both healthy and disease controls and primary Sjögren's syndrome patients were non-reactive to these sequences. Limited proteolysis of CRT with two major leucocyte serine proteases, elastase and cathepsin G, demonstrated that an N-terminal region of CRT is resistant to digestion. Interestingly, some of the epitopes with the highest reactivity belong to the fragments of the protein which bind to C1q and inhibit complement activation. Whether C1q association with CRT is a pathological or protective interaction between these two proteins is currently under investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792392      PMCID: PMC1905652          DOI: 10.1046/j.1365-2249.2000.01214.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites.

Authors:  J M Parker; D Guo; R S Hodges
Journal:  Biochemistry       Date:  1986-09-23       Impact factor: 3.162

Review 2.  Antiphospholipid antibodies.

Authors:  E N Harris
Journal:  Br J Haematol       Date:  1990-01       Impact factor: 6.998

3.  A major autoepitope is present on the amino terminus of a human SS-A/Ro polypeptide.

Authors:  T S Lieu; M M Newkirk; F C Arnett; L A Lee; J S Deng; J D Capra; R D Sontheimer
Journal:  J Autoimmun       Date:  1989-08       Impact factor: 7.094

4.  The systemic lupus erythematosus (SLE) disease autoantigen-calreticulin can inhibit C1q association with immune complexes.

Authors:  U Kishore; R D Sontheimer; K N Sastry; E G Zappi; G R Hughes; M A Khamashta; K B Reid; P Eggleton
Journal:  Clin Exp Immunol       Date:  1997-05       Impact factor: 4.330

Review 5.  Pathophysiological roles of calreticulin in autoimmune disease.

Authors:  P Eggleton; D H Llewellyn
Journal:  Scand J Immunol       Date:  1999-05       Impact factor: 3.487

6.  Molecular characterization of human Ro/SS-A antigen. Amino terminal sequence of the protein moiety of human Ro/SS-A antigen and immunological activity of a corresponding synthetic peptide.

Authors:  T S Lieu; M M Newkirk; J D Capra; R D Sontheimer
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

Review 7.  Molecular characterization of the Ro/SS-A autoimmune response.

Authors:  R D Sontheimer; T S Lieu; D P McCauliffe
Journal:  Semin Dermatol       Date:  1991-09

8.  Cloning of the gene encoding a Schistosoma mansoni antigen homologous to human Ro/SS-A autoantigen.

Authors:  J Khalife; F Trottein; A M Schacht; C Godin; R J Pierce; A Capron
Journal:  Mol Biochem Parasitol       Date:  1993-02       Impact factor: 1.759

9.  Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study.

Authors:  M Petri; M Genovese; E Engle; M Hochberg
Journal:  Arthritis Rheum       Date:  1991-08

10.  Immunoglobulin class and subclass profile of the Ro/SS-A autoantibody response.

Authors:  T S Lieu; C B Reimer; R D Sontheimer
Journal:  J Invest Dermatol       Date:  1988-02       Impact factor: 8.551

View more
  12 in total

1.  Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.

Authors:  Elisa ten Hacken; Maria Gounari; Jaap Willem Back; Ekaterina Shimanovskaya; Lydia Scarfò; Ekaterina Kim; Jared Burks; Maurilio Ponzoni; Giuseppe Alvise Ramirez; William G Wierda; Zeev Estrov; Michael J Keating; Alessandra Ferrajoli; Kostas Stamatopoulos; Paolo Ghia; Jan A Burger
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

2.  Calreticulin binds preferentially with B cell linear epitopes of Ro60 kD autoantigen, enhancing recognition by anti-Ro60 kD autoantibodies.

Authors:  E V Staikou; J G Routsias; A A Makri; A Terzoglou; M Sakarellos-Daitsiotis; C Sakarellos; G Panayotou; H M Moutsopoulos; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

3.  Association of calreticulin expression with disease activity and organ damage in systemic lupus erythematosus patients.

Authors:  Yichao Wang; Jiaogui Xie; Zhili Liu; Hongwei Fu; Qianyu Huo; Yajun Gu; Yunde Liu
Journal:  Exp Ther Med       Date:  2017-03-20       Impact factor: 2.447

4.  Cross-reactivity of Schistosoma mansoni cytosolic superoxide dismutase, a protective vaccine candidate, with host superoxide dismutase and identification of parasite-specific B epitopes.

Authors:  Claudia Carvalho-Queiroz; Rosemary Cook; Ching C Wang; Rodrigo Correa-Oliveira; Nicola A Bailey; Nejat K Egilmez; Edith Mathiowitz; Philip T LoVerde
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

5.  Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women.

Authors:  Jon J Ladd; Timothy Chao; Melissa M Johnson; Ji Qiu; Alice Chin; Rebecca Israel; Sharon J Pitteri; Jianning Mao; Mei Wu; Lynn M Amon; Martin McIntosh; Christopher Li; Ross Prentice; Nora Disis; Samir Hanash
Journal:  Cancer Res       Date:  2012-12-26       Impact factor: 12.701

Review 6.  Endoplasmic Reticulum Stress Interacts With Inflammation in Human Diseases.

Authors:  Stewart Siyan Cao; Katherine L Luo; Lynn Shi
Journal:  J Cell Physiol       Date:  2016-02       Impact factor: 6.384

Review 7.  Coherent somatic mutation in autoimmune disease.

Authors:  Kenneth Andrew Ross
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

Review 8.  Pathophysiology of cutaneous lupus erythematosus.

Authors:  Julie H Lin; Jan P Dutz; Richard D Sontheimer; Victoria P Werth
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 10.817

9.  Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes.

Authors:  Vincent Goëb; Marlène Thomas-L'Otellier; Romain Daveau; Roland Charlionet; Patrice Fardellone; Xavier Le Loët; François Tron; Danièle Gilbert; Olivier Vittecoq
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

10.  A Master Autoantigen-ome Links Alternative Splicing, Female Predilection, and COVID-19 to Autoimmune Diseases.

Authors:  Julia Y Wang; Michael W Roehrl; Victor B Roehrl; Michael H Roehrl
Journal:  bioRxiv       Date:  2021-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.